Trilaciclib - Latest Advances

ToPCourT protocol: a phase II trial of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced/unresectable or metastatic triple-negative breast cancer.

Journal: Future oncology (London, England)

Published: March 11, 2026

NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer.

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

Efficacy and safety of trilaciclib to prevent chemotherapy-induced myelosuppression in advanced solid tumors: a systematic review and meta-analysis.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 01, 2025

The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC.

Journal: Immunotherapy

Published: September 11, 2025

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis.

Journal: Nature genetics

Published: September 09, 2025

Case Report: Analysis of short-term clinical efficacy of trilaciclib in patients with advanced lung neuroendocrine carcinoma undergoing chemotherapy.

Journal: Frontiers in oncology

Published: August 14, 2025

CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: July 19, 2025

Comparing the Efficacy of Various Treatment Strategies for Patients With Advanced Triple-Negative Breast Cancer: An Umbrella Review.

Journal: Clinical pharmacology and therapeutics

Published: June 18, 2025

Application value and safety of trilaciclib in first-line chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer: A real-world study.

Journal: Oncology letters

Published: May 23, 2025

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update.

Journal: Pharmacological research

Published: March 29, 2025

HSR25-156: Myelosuppression and Healthcare Resource Utilization in Community Oncology Patients With Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy With or Without Trilaciclib.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: March 10, 2025